Manfred Schwab

German Cancer Research Center — Germany

Medicine · Health Sciences

57h-index17.2kcitations1.5kworks0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(155), Cancer, Hypoxia, and Metabolism(51), Sarcoma Diagnosis and Treatment(35), Neuroendocrine Tumor Research Advances(35), Cancer Genomics and Diagnostics(32)

Publications1.5k total

A journey to excellence: Disseminating groundbreaking discoveries in oncology research
Cancer Letters·2023· 2 cited
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data from High <i>Skp2</i> Expression Characterizes High-Risk Neuroblastomas Independent of <i>MYCN</i> Status
2023Open Access
Data from High <i>Skp2</i> Expression Characterizes High-Risk Neuroblastomas Independent of <i>MYCN</i> Status
2023Open Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Data from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data from High <i>Skp2</i> Expression Characterizes High-Risk Neuroblastomas Independent of <i>MYCN</i> Status
2023Open Access
Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Data from High <i>Skp2</i> Expression Characterizes High-Risk Neuroblastomas Independent of <i>MYCN</i> Status
2023Open Access
page 1 of 74Next →

Frequent Co-authors

Frank Westermann(11), Frank Berthold(10), J. Michael Bishop(7), Harold Varmus(6), Barbara Hero(5), Matthias Fischer(5), Lukas C. Amler(5), Kari Alitalo(4), André Oberthuer(4), Benedikt Brors(4), Javed Khan(3), Jun S. Wei(3), Garrett M. Brodeur(3), Robert C. Seeger(3), Yvonne Kahlert(3), Roland Eils(3), Jo Vandesompele(3), Larissa Savelyeva(3), Jeffrey M. Trent(2), Kathy Boon(2)